EUVIMEDEUVIMED entdecken
Open Access

Cardiac tertiary immune niches drive immune activation in immune checkpoint inhibitor myocarditis

Carly C Tymm iD, Matthieu Paiola iD, Shoiab Bukhari, Xizi Hu iD, Robert Winchester iD, Adam Mor iD

Science Advances · 2026

DOI: 10.1126/sciadv.aed8359 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, 2026. Verfasst von Carly C Tymm und 5 weiteren Autor:innen. Beteiligte Einrichtung: Columbia Center for Translational Immunology, Department of Medicine, Columbia University Medical Center, New York, NY 10032, USA. Hauptthemen laut MEDLINE: Myocarditis, Immune Checkpoint Inhibitors, Myocardium, Tertiary Lymphoid Structures. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitor (ICI) myocarditis is a rare but frequently fatal immune-related adverse event of cancer immunotherapy. Understanding the mechanisms of this toxicity is critical to balancing treatment with maintenance of antitumor immunity. Using integrated spatial and single-cell analyses in a pharmacological murine model, we identified regional infiltration of Ly6C + monocytes and PD-1 + CD8 + T cells in the heart that organize into fibroblast-rich immune structures, which we term tertiary T cell niches (TTCNs). TTCNs serve as hubs for T cell activation, sharing features of tertiary lymphoid structures. A TTCN gene signature was strongly enriched in cardiac tissue from patients with ICI myocarditis. Complementary T cell receptor analyses revealed clonal expansion of cardiac T cells following ICI treatment. We further identified TTCN-associated cytokines and structural proteins as candidate therapeutic targets to reduce myocardial inflammation while considering tumor control. Together, these findings suggest that cardiac tertiary immune structures play a central role in ICI myocarditis and highlight pathways that could mitigate ICI cardiotoxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MyocarditisImmune Checkpoint InhibitorsMyocardiumTertiary Lymphoid StructuresAnimalsMiceHumansCD8-Positive T-LymphocytesLymphocyte ActivationMonocytesAntigens, LyProgrammed Cell Death 1 ReceptorDisease Models, Animal

Substanzen

Immune Checkpoint InhibitorsAntigens, LyProgrammed Cell Death 1 ReceptorLy-6C antigen, mouse

Autor:innen und Institutionen

  • Columbia Center for Translational Immunology, Department of Medicine, Columbia University Medical Center, New York, NY 10032, USA.
  • Division of Rheumatology, Department of Medicine, Columbia University Medical Center, New York, NY 10032, USA.
  • Herbert Irvine Comprehensive Cancer Center, Columbia University Medical Center, New York, NY 10032, USA.

ORCID-Profile: Carly C Tymm, Matthieu Paiola, Xizi Hu, Robert Winchester, Adam Mor

Förderung

  • NIAID NIH HHS
  • NIH HHS
  • NCI NIH HHS
  • NCATS NIH HHS
  • National Institutes of Health

Zitieren

APA

Tymm, C. C., Paiola, M., Bukhari, S., Hu, X., Winchester, R., & Mor, A. (2026). Cardiac tertiary immune niches drive immune activation in immune checkpoint inhibitor myocarditis. Science Advances. https://doi.org/10.1126/sciadv.aed8359

Vancouver

Tymm CC, Paiola M, Bukhari S, Hu X, Winchester R, Mor A. Cardiac tertiary immune niches drive immune activation in immune checkpoint inhibitor myocarditis. Science Advances. 2026. doi:10.1126/sciadv.aed8359

BibTeX
@article{Tymm2026,
  author = {Tymm, Carly C and Paiola, Matthieu and Bukhari, Shoiab and Hu, Xizi and Winchester, Robert and Mor, Adam},
  title = {Cardiac tertiary immune niches drive immune activation in immune checkpoint inhibitor myocarditis},
  journal = {Science Advances},
  year = {2026},
  doi = {10.1126/sciadv.aed8359}
}
Kostenlos starten →